You are here:

darunavir cobicistat (Rezolsta)

Advice

following a full submission

darunavir/cobicistat (Rezolsta®) is accepted for use within NHS Scotland.

Indication under review: In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.

Pharmacokinetic studies have demonstrated that darunavir/cobicistat is bioequivalent (in terms of darunavir exposure) to ritonavir-boosted darunavir. No comparative efficacy studies have been reported.

Drug Details

Drug Name: darunavir cobicistat (Rezolsta)
SMC Drug ID: 1081/15
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 August 2015

Back